Stabilis

Haloperidol lactate



Noms commerciaux

Aloperidin	Grèce
Aloperidolo	Italie
Haldol	Allemagne, Australie, Autriche, Belgique, Chili, Danemark, Equateur, Finlande, France, Grèce, Hongrie, Irlande, Islande, Japon, Luxembourg, Malaisie, Maroc, Mexique, Norvège, Pologne, Suède, Suisse, Tunisie, Vénézuela
Halodic	Iran
Halonace	Egypte
Haloperidol	Colombie, Egypte, Equateur, Grande Bretagne, Hongrie, Iran, Pérou, Portugal
Halopidol	Argentine, Colombie
Haloprol	Egypte
Manace	Malaisie
Norodol	Turquie
Serenace	Australie, Grande Bretagne, Irlande, Nouvelle Zélande
Serenase	Italie
Serenelfi	Portugal
Sylador	Arabie Saoudite

Stabilité des solutions

		0.1 mg/ml	24°C		38			605

Stabilité en mélange

PVC		52 mg/ml	21°C		Glycopyrronium bromide : 15 mg/ml Buprenorphine hydrochloride : 57 mg/ml	30	2113
PVC		52 mg/ml	36°C		Glycopyrronium bromide : 15 mg/ml Buprenorphine hydrochloride : 57 mg/ml	9	2113

PVC		0,02 >> 0,2 mg/ml	37°C	?	Morphine hydrochloride : 0.2 >> 18 mg/ml	7	2362
PVC		52 mg/ml	4°C		Glycopyrronium bromide : 15 mg/ml Buprenorphine hydrochloride : 57 mg/ml	30	2113
PP		52 mg/ml	21°C		Glycopyrronium bromide : 15 mg/ml Buprenorphine hydrochloride : 57 mg/ml	30	2113
PP		0,42 & 0,62 mg/ml	25°C		Scopolamine N-butyl bromide : 5 & 6,67 mg/ml Morphine hydrochloride : 1,67>> 10 mg/ml	15	2055
PP		0,208 mg/ml	25°C		Tramadol hydrochloride : 8,33 mg/ml	15	2024
PP		0,625 mg/ml	25°C		Tramadol hydrochloride : 33,33 mg/ml	15	2024
PP		52 mg/ml	36°C		Glycopyrronium bromide : 15 mg/ml Buprenorphine hydrochloride : 57 mg/ml	16	2113
PP		0,312 mg/ml	4°C		Scopolamine N-butyl bromide : 2,5 & 5 & 10 mg/ml	15	1970
PP		0,208 mg/ml	4°C		Tramadol hydrochloride : 8,33 mg/ml	15	2024
PP		0,625 mg/ml	4°C		Tramadol hydrochloride : 33,33 mg/ml	15	2024
PP		52 mg/ml	4°C		Glycopyrronium bromide : 15 mg/ml Buprenorphine hydrochloride : 57 mg/ml	30	2113
POF		0,05 mg/ml	- 20°C		Dexketoprofen : 2,5 mg/ml Tramadol hydrochloride : 5 mg/ml	30	3297
POF		0,05 mg/ml	25°C	±	Dexketoprofen : 2,5 mg/ml Tramadol hydrochloride : 5 mg/ml	30	3297
POF		0,05 mg/ml	4°C		Dexketoprofen : 2,5 mg/ml Tramadol hydrochloride : 5 mg/ml	30	3297
POF		0,05 mg/ml	- 20°C		Dexketoprofen : 2,5 mg/ml Tramadol hydrochloride : 5 mg/ml	30	3297
POF		0,05 mg/ml	25°C	±	Dexketoprofen : 2,5 mg/ml Tramadol hydrochloride : 5 mg/ml	30	3297
POF		0,05 mg/ml	4°C		Dexketoprofen : 2,5 mg/ml Tramadol hydrochloride : 5 mg/ml	30	3297
EVA		0,02 >> 0,2 mg/ml	2-8°C		Morphine hydrochloride : 0.2 >> 18 mg/ml	14	2362
EVA		0,02 >> 0,2 mg/ml	37°C	?	Morphine hydrochloride : 0.2 >> 18 mg/ml	7	2362
PP		0,75 mg/ml	18-22°C		Diamorphine hydrochloride : 20 mg/ml	20	1886
PP		0,5 mg/ml	25°C	?	Scopolamine hydrobromide : 0,04 mg/ml Famotidine : 0,4 mg/ml Dimenhydrinate : 5 mg/ml Hydromorphone hydrochloride : 10 mg/ml	12	2166
PP		0,5 mg/ml	25°C	?	Metoclopramide hydrochloride : 0,5 mg/ml Hydromorphone hydrochloride : 10 mg/ml	96	2166
PP		0,5 mg/ml	4°C	?	Scopolamine hydrobromide : 0,04 mg/ml Famotidine : 0,4 mg/ml Dimenhydrinate : 5 mg/ml Hydromorphone hydrochloride : 10 mg/ml	12	2166
PP	∅	0,31 mg/ml	22°C-24°C	±	Diamorphine hydrochloride : 6,25 & 12,5 mg/ml	24	779
PP	∅	0,31 mg/ml	4-8°C		Diamorphine hydrochloride : 6,25 & 12,5 mg/ml	7	779
?		0,208 >> 0,624 mg/ml	25°C		Scopolamine N-butyl bromide : 3,33 >> 6,67 mg/ml Tramadol hydrochloride : 8,8 >> 33,3 mg/ml	15	3132

Facteur influençant la stabilité

					230
	RL				230
	0.45				230
					1415
	NaH CO3				3466 3823

Compatibilités

		Haloperidol lactate : 0.2 mg/ml Allopurinol sodium : 3 mg/ml		307
		Haloperidol lactate : 0.2 mg/ml Amifostine : 10 mg/ml		3
		Haloperidol lactate : 0.5 mg/ml Amiodarone hydrochloride : 15 mg/ml		3823
		Haloperidol lactate : 0.5 mg/ml Amiodarone hydrochloride : 15 mg/ml		3823
		Haloperidol lactate Amiodarone hydrochloride		3464
		Haloperidol lactate : 5 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Haloperidol lactate : 0.2 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Haloperidol lactate : 0.2 mg/ml Amsacrine : 1 mg/ml		253
		Haloperidol lactate : 0.2 mg/ml Aztreonam : 40 mg/ml		99
15'		Haloperidol lactate : 1.67 mg/ml Benztropine mesylate : 0.67 mg/ml	∅	1643
		Haloperidol lactate : 1.67 >> 3.33 mg/ml Benztropine mesylate : 0.33 >> 0.67 mg/ml	∅	1724
		Haloperidol lactate : 2 mg/ml Benztropine mesylate : 2 mg/ml		229
		Haloperidol lactate : 5 mg/ml Benztropine mesylate : 1 mg/ml		188
		Haloperidol lactate : 0,5 >>>5 mg/ml Benztropine mesylate : 0.5 mg/ml		229
?		Haloperidol lactate : 5 mg/ml Bivalirudin		3539
		Haloperidol lactate : 0.2 mg/ml Bivalirudin : 5 mg/ml		1713
		Haloperidol lactate : 0.2 mg/ml Bivalirudin		3539

		Haloperidol lactate : 5 mg/ml Cefmetazole sodium : 100 mg/ml		93
		Haloperidol lactate : 0,2 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Haloperidol lactate		605
		Haloperidol lactate : 0,2 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Haloperidol lactate : 0,2 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Haloperidol lactate : 0.2 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Haloperidol lactate Ceftobiprole medocaril sodium		4650
		Haloperidol lactate : 0.2 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Haloperidol lactate : 0.2 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
		Haloperidol lactate : 0.5 & 5 mg/ml Cimetidine hydrochloride : 6 mg/ml		403
		Haloperidol lactate : 0.2 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Haloperidol lactate : 0.2 mg/ml Cladribine : 0.015 mg/ml		1496
		Haloperidol lactate : 0.2 mg/ml Cladribine : 0.5 mg/ml		1496
		Haloperidol lactate : 0.5 mg/ml Clonazepam : 0.2 mg/ml		3823
		Haloperidol lactate : 0.5 mg/ml Clonidine hydrochloride : 0.012 mg/ml		3823
		Haloperidol lactate : 0,21 & 0,62 mg/ml Dexamethasone sodium phosphate : 0,44 & 1,33 mg/ml		1971
		Haloperidol lactate : 0,25 >> 0,5 mg/ml Dexamethasone sodium phosphate : 0,2 >>0,4 mg/ml		4404
		Haloperidol lactate : 0,25 >> 0,5 mg/ml Dexamethasone sodium phosphate : 0,2 >>0,4 mg/ml		4404
		Haloperidol lactate : 0.2 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Haloperidol lactate : 0.31 mg/ml Diamorphine hydrochloride : 6.25 & 12.5 mg/ml	∅	779
		Haloperidol lactate : 0.16 >> 0.45 mg/ml Diamorphine hydrochloride : 45.45 >> 145.16 mg/ml	∅	1230
		Haloperidol lactate : 0.18 mg/ml Diamorphine hydrochloride : 18.18 mg/ml	∅	1230
		Haloperidol lactate Diamorphine hydrochloride		4982
		Haloperidol lactate : 0.75 mg/ml Diamorphine hydrochloride : 20 >> 100 mg/ml		1886
		Haloperidol lactate : 5 mg/ml Diphenhydramine hydrochloride : 50 mg/ml		188
		Haloperidol lactate : 2 & 3 mg/ml	RL	230
		Haloperidol lactate : 0.5 & 5 mg/ml Dopamine hydrochloride : 1.6 mg/ml		403

		Haloperidol lactate	NaH CO3	3466
		Haloperidol lactate Diphenhydramine hydrochloride		985
		Haloperidol lactate : 5 mg/ml Diphenhydramine hydrochloride : 50 mg/ml		982
		Haloperidol lactate : 0,5 mg/ml	NaH CO3	3823
		Haloperidol lactate : 0.2 mg/ml		301
		Haloperidol lactate : 0.5 & 5 mg/ml Dobutamine hydrochloride : 4 mg/ml		403
		Haloperidol lactate : 0.2 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Haloperidol lactate : 10 mg/ml		939
		Haloperidol lactate : 0.2 mg/ml Docetaxel : 0.9 mg/ml		1754
		Haloperidol lactate : 0.2 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Haloperidol lactate : 0.2 mg/ml Famotidine : 2 mg/ml		215
		Haloperidol lactate : 0.5 & 5 mg/ml Famotidine : 0.267 mg/ml		403
		Haloperidol lactate : 0.2 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Haloperidol lactate : 0.2 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Haloperidol lactate : 5 mg/ml	RL	4603
		Haloperidol lactate : 2 & 3 mg/ml	0.45	230
		Haloperidol lactate : 0.2 mg/ml		1415
		Haloperidol lactate : 0.2 mg/ml Fentanyl citrate : 25 µg/ml		1974
		Haloperidol lactate : 0.2 mg/ml Filgrastim : 30 µg/ml		244
		Haloperidol lactate : 5 mg/ml Fluconazole : 2 mg/ml		496
		Haloperidol lactate : 5 mg/ml Foscarnet sodium : 24 mg/ml	∅	73
		Haloperidol lactate Furosemide		3465
		Haloperidol lactate : 0,5 mg/ml Furosemide : 10 mg/ml		3463
		Haloperidol lactate : 0,5 mg/ml Furosemide : 10 mg/ml	∅	3134
		Haloperidol lactate : 0,5 mg/ml Furosemide : 10 mg/ml		3823
		Haloperidol lactate : 5 mg/ml Gallium nitrate : 1 mg/ml		91
		Haloperidol lactate : 0.2 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Haloperidol lactate : 0.2 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182

		Haloperidol lactate Heparin sodium		3540
		Haloperidol lactate : 5 mg/ml Heparin sodium : 100 & 200 UI/ml	◆	617
		Haloperidol lactate : 0.5 mg/ml Heparin sodium : 500 UI/ml	▲	3823
		Haloperidol lactate : 5 mg/ml Heparin sodium : 100 & 200 UI/ml	▲	617
		Haloperidol lactate : 0.2 mg/ml Hetastarch : 60 mg/ml	R	1721
		Haloperidol lactate : 5 mg/ml Hydromorphone hydrochloride : 1 mg/ml	∅	216
		Haloperidol lactate : 2 mg/ml Hydromorphone hydrochloride : 1 mg/ml	∅	216
		Haloperidol lactate Hydromorphone hydrochloride		5073
		Haloperidol lactate : 0.2 mg/ml Hydromorphone hydrochloride : 0.5 mg/ml	◆	1974
		Haloperidol lactate : 1 mg/ml Hydromorphone hydrochloride : 10 mg/ml	∅	216
		Haloperidol lactate : 2 mg/ml Hydromorphone hydrochloride : 10 mg/ml	∅	216
		Haloperidol lactate : 5 mg/ml Hydromorphone hydrochloride : 10 mg/ml	∅	216
		Haloperidol lactate : 1 mg/ml Hydromorphone hydrochloride : 1 mg/ml	∅	216
		Haloperidol lactate : 5 mg/ml Hydroxyzine dihydrochloride : 50 mg/ml		188
		Haloperidol lactate : 5 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml	◆	4433
		Haloperidol lactate : 0.5 mg/ml Insulin : 2 UI/ml	▲	3823
		Haloperidol lactate : 5 mg/ml Ketorolac tromethamine : 30 mg/ml	∅	228
		Haloperidol lactate : 0.2 mg/ml Lansoprazole : 0.55 mg/ml	▲	1625
		Haloperidol lactate : 0.25 >> 0.5 mg/ml Levomepromazine : 0.625 >> 2.5 mg/ml	◆	4404
		Haloperidol lactate : 0.25 >> 0.5 mg/ml Levomepromazine : 0.625 >> 2.5 mg/ml	▲	4404
		Haloperidol lactate : 0.5 & 5 mg/ml Lidocaine hydrochloride : 4 mg/ml	◆	403
		Haloperidol lactate : 0.2 mg/ml Linezolid : 2 mg/ml	∅	1925
		Haloperidol lactate : 0.5 & 5 mg/ml Lorazepam : 0.33 mg/ml	▲	186
		Haloperidol lactate : 0.2 mg/ml Melphalan : 0.1 mg/ml	▲	169
		Haloperidol lactate : 0.2 mg/ml Methadone hydrochloride : 1 mg/ml	◆	1974
		Haloperidol lactate : 0.25 >> 0.5 mg/ml Metoclopramide hydrochloride : 3 mg/ml	◆	4404

		Haloperidol lactate : 0.21 & 0.62 mg/ml Metoclopramide hydrochloride : 1.11 & 3.33 mg/ml		1971
		Haloperidol lactate : 0.25 >> 0.5 mg/ml Metoclopramide hydrochloride : 3 mg/ml		4404
		Haloperidol lactate : 0.5 & 5 mg/ml Midazolam hydrochloride : 5 mg/ml		186
		Haloperidol lactate : 0,12 >> 0,8 mg/ml Midazolam hydrochloride : 0,04 & 0,08 mg/ml		4366
		Haloperidol lactate : 0.5 mg/ml Midazolam hydrochloride : 2.1 mg/ml		3823
		Haloperidol lactate : 0.25 >> 0.5 mg/ml Midazolam hydrochloride : 1.2 mg/ml		4404
		Haloperidol lactate : 0,12 >> 0,8 mg/ml Midazolam hydrochloride : 0,04 & 0,08 mg/ml		4366
		Haloperidol lactate : 0.25 >> 0.5 mg/ml Midazolam hydrochloride : 1.2 mg/ml		4404
		Haloperidol lactate : 0.21 & 0.62 mg/ml Midazolam hydrochloride : 0.5 & 1.5 mg/ml		1971
		Haloperidol lactate : 4 mg/ml Morphine hydrochloride : 3 > 50 mg/ml		1866
		Haloperidol lactate : 0.21 & 0.62 mg/ml Morphine hydrochloride : 1.68 & 5 mg/ml		1971
		Haloperidol lactate : 0.25 >> 0.5 mg/ml Morphine hydrochloride : 2 >> 5 mg/ml		4404
		Haloperidol lactate : 0.25 >> 0.5 mg/ml Morphine hydrochloride : 2 >> 5 mg/ml		4404
		Haloperidol lactate : 3 mg/ml Morphine hydrochloride : 5 > 50 mg/ml		1866
		Haloperidol lactate : 2 mg/ml Morphine hydrochloride : 15 > 50 mg/ml		1866
		Haloperidol lactate : 5 mg/ml Morphine hydrochloride : 1 mg/ml		1866
		Haloperidol lactate : 4 mg/ml Morphine hydrochloride : 1 & 2 mg/ml		1866
		Haloperidol lactate : 3 mg/ml Morphine hydrochloride : 1 >> 3 mg/ml		1866
		Haloperidol lactate : 2 mg/ml Morphine hydrochloride : 1 >> 10 mg/ml		1866
		Haloperidol lactate : 0.02 >> 0.2 mg/ml Morphine hydrochloride : 0.2 >> 18 mg/ml		2362
		Haloperidol lactate : 5 mg/ml Morphine hydrochloride : 2 > 50 mg/ml		1866
		Haloperidol lactate : 2.5 mg/ml Morphine sulfate : 2,5 & 5 mg/ml		1492
		Haloperidol lactate : >1 mg/ml		230
		Haloperidol lactate : 2.5 mg/ml Morphine hydrochloride : 2.5 >> 15 mg/ml		1757
		Haloperidol lactate : 1 mg/ml Morphine hydrochloride : 1 >> 20 mg/ml		1866
		Haloperidol lactate : 2.5 mg/ml Morphine sulfate : 2,5 & 5 mg/ml		1492

		Haloperidol lactate : 0.2 mg/ml Morphine sulfate : 1 mg/ml		1974
		Haloperidol lactate : 0.5 mg/ml Nimodipine : 0.2 mg/ml		3823
		Haloperidol lactate : 0.5 mg/ml Nitroglycerin : 0.2 mg/ml		3823
		Haloperidol lactate : 0.5 mg/ml Nitroglycerin : 0.2 mg/ml		3823
		Haloperidol lactate : 0.5 & 5 mg/ml Nitroglycerin : 0.4 mg/ml		403
		Haloperidol lactate : 5 mg/ml Nitroprusside sodium : 0.2 mg/ml		403
		Haloperidol lactate : 0.5 mg/ml Nitroprusside sodium : 0.2 mg/ml		403
		Haloperidol lactate : 0.5 & 5 mg/ml Norepinephrine bitartrate : 0.032 mg/ml		403
		Haloperidol lactate : 0,5 mg/ml Omeprazole sodium : 1,6 mg/ml		3823
		Haloperidol lactate : 0.02 >> 0.08 mg/ml Ondansetron hydrochloride : 0.064 mg/ml		4036
		Haloperidol lactate : 0.02 >> 0.08 mg/ml Ondansetron hydrochloride : 0.064 mg/ml		4036
		Haloperidol lactate : 0.02 >> 0.08 mg/ml Ondansetron hydrochloride : 0.032 mg/ml		4036
		Haloperidol lactate : 0.02 >> 0.08 mg/ml Ondansetron hydrochloride : 0.032 mg/ml		4036
		Haloperidol lactate : 0.2 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Haloperidol lactate : 0.15 & 0.3 mg/ml Ondansetron hydrochloride : 0.25 & 0.4 mg/ml		4082
		Haloperidol lactate : 1 mg/ml Oritavancin : 0.8 >>2 mg/ml		3152
		Haloperidol lactate : 0,2 mg/ml Oxaliplatin : 0,5 mg/ml		1662
		Haloperidol lactate : 0.1 & 0.7 mg/ml Oxycodone hydrochloride : 1 & 8.7 mg/ml		2125
		Haloperidol lactate : 0.4 & 1.2 mg/ml Oxycodone hydrochloride : 14.7 & 38.5 mg/ml		2900
		Haloperidol lactate : 0.1 & 0.7 mg/ml Oxycodone hydrochloride : 1 & 8.7 mg/ml		2125
		Haloperidol lactate : 0.4 & 1.2 mg/ml Oxycodone hydrochloride : 14.7 & 38.5 mg/ml		2900
		Haloperidol lactate : 0.2 mg/ml Paclitaxel : 1.2 mg/ml		85
		Haloperidol lactate : 5 mg/ml Paracetamol : 10 mg/ml		4435
		Haloperidol lactate : 5 mg/ml Paracetamol : 10 mg/ml		4742
		Haloperidol lactate : 0.2 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Haloperidol lactate : 0.5 & 5 mg/ml Phenylephrine hydrochloride : 0.02 mg/ml		403

		Haloperidol lactate : 0.2 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml	◆	81
		Haloperidol lactate : 0.2 mg/ml Propofol : 10 mg/ml	∅	300
		Haloperidol lactate : 0,2 mg/ml Quinupristine/dalfopristine : 2 mg/ml	◆	1513
		Haloperidol lactate : 0.2 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml	▲	59
		Haloperidol lactate : 0.5 mg/ml Remifentanil hydrochloride : 100 µg/ml	▲	3823
		Haloperidol lactate : 0.2 mg/ml Sargramostim : 10 µg/ml	▲	335
		Haloperidol lactate : 0.21 & 0.62 mg/ml Scopolamine N-butyl bromide : 1.68 & 5 mg/ml	▲	1971
		Haloperidol lactate : 0.25 >> 0.5 mg/ml Scopolamine N-butyl bromide : 3-7 mg/ml	▲	4404
		Haloperidol lactate : 0,3125 >> 1,25 mg/ml Scopolamine N-butyl bromide : 2,5 >> 10 mg/ml	▲	1970
		Haloperidol lactate : 0.25 >> 0.5 mg/ml Scopolamine N-butyl bromide : 3-7 mg/ml	◆	4404
		Haloperidol lactate : 0.5 mg/ml Sodium bicarbonate : 84 mg/ml	∅	3212
		Haloperidol lactate : 0.5 mg/ml Sodium bicarbonate : 84 mg/ml	▲	3823
		Haloperidol lactate Sodium bicarbonate		3466
		Haloperidol lactate : 2,5 mg/ml Tacrolimus : 1000 µg/ml	▲	479
		Haloperidol lactate : 0.2 mg/ml Teniposide : 0.1 mg/ml	◆	905
		Haloperidol lactate : 0.5 & 5 mg/ml Theophylline : 1.6 mg/ml	◆	403
		Haloperidol lactate : 0.2 mg/ml Thiotepa : 1 mg/ml	◆	249
		Haloperidol lactate Tigecycline	▲	3332
		Haloperidol lactate : 0.208 >> 0.625 mg/ml Tramadol hydrochloride : 8.33 >> 33.33 mg/ml	▲	2024
		Haloperidol lactate : 0.21 & 0.62 mg/ml Tramadol hydrochloride : 11.18 & 33.3 mg/ml	▲	1971
		Haloperidol lactate : 0.5 mg/ml Urapidil : 5 mg/ml	▲	3823
		Haloperidol lactate : 0,5 mg/ml Valproic acid : 16 mg/ml	▲	3823
		Haloperidol lactate : 0.2 mg/ml Vinorelbine tartrate : 1 mg/ml	▲	84

Voie d'administration



Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
73	Revue	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
85	Revue	Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 1716-1719.
91	Revue	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
93	Revue	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
186	Revue	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
188	Revue	Gibler B, Kim MS, Raleigh F. Visual compatibility of neuroleptics with anticholinergics or antihistamines in polyethylene syringes. Am J Hosp Pharm 1994 ; 51: 2709-2710.

215	Revue	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
216	Revue	Huang E, Anderson RP. Compatibility of hydromorphone hydrochloride with haloperidol lactate and ketorolac tromethamine. Am J Hosp Pharm 1994 ; 51: 2963.
228	Revue	Mendenhall A, Hoyt DB. Incompatibility of ketorolac tromethamine with haloperidol lactate and triethylperazine maleate. Am J Hosp Pharm 1994 ; 51: 2964.
229	Revue	Jackson CW, Cunningham K. Compatibility of haloperidol lactate with benztropine mesylate. Am J Hosp Pharm 1994 ; 51: 2962-2963.
230	Revue	Fraser GL, Riker RR. Visual compatibility of haloperidol lactate with injectable solutions. Am J Hosp Pharm 1994 ; 51: 905-906.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	Revue	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
403	Revue	Outman WR, Monolakis J. Visual compatibility of haloperidol lactate with 0.9% sodium chloride injection or injectable critical-care drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 1539-1541.

479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
605	Revue	Das Gupta V, Stewart KR. Stability of haloperidol in 5% dextrose injection. Am J Hosp Pharm 1982 ; 39: 292-294.
617	Revue	Solomon DA, Nasinnyk KK. Compatibility of haloperidol lactate and heparin sodium. Am J Hosp Pharm 1982 ; 39: 843-844.
779	Revue	Collins AJ, Abethell JA, Holmes SG, Rain R. Stability of diamorphine hydrochloride with haloperidol in prefilled syringes for continuous subcutaneous administration. J Pharm Pharmacol 1986 ; 38: 51P.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
939	Revue	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
982	Revue	Ukhun IA. Compatibility of haloperidol and diphenhydramine in a hypodermic syringes. Ann Pharmacotherapy 1995 ; 29: 1168.
985	Revue	Raleigh FR, Gibler BS. Haloperidol and diphenhydramine compatibility. Ann Pharmacotherapy 1996 ; 30: 549.
1230	Revue	Regnard C, Pashley S, Westrope F. Anti-emetic / diamorphine mixture compatibility in infusion pumps. Br J Pharm Pract 1986 ; 8: 218-220.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1492	Revue	LeBelle MJ, Savard C, Gagnon A. Compatibility of morphine and midazolam or haloperidol in parenteral admixtures. Can J Hosp Pharm 1995 ; 48: 155-160.

1496	Revue	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1513	Laboratoire	Quinupristine / dalfopristine (Synercid®) - Résumé des caractéristiques du produit Monarch Pharmaceuticals Ireland 2006
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1643	Revue	Raleigh F, Gibler B. Haldol-benztropine incompatibility. Hosp Pharm 1994 ; 29: 76.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1724	Revue	Elbe D, Condé C. Visual compatibility of various injectable neuroleptic agents with benztropine and lorazepam in polypropylene syringes. Can J Hosp Pharm 2001 ; 54: 102-105.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1757	Revue	Schrijvers D, Tai-Apin C, De Smet MC, Cornil P, Vermorken JB, Bruyneel P. Determination of compatibility and stability of drugs used in palliative care. J Clin Pharm Ther 1998 ; 23: 311-314.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1866	Revue	Vermeire A, Remon JP. Compatibility and stability of morphine in binary admixtures with haloperidol, midazolam, dexamethasone or methylprednisolone. Int J Pharm 1998 ; 174: 157-177.
1886	Revue	Allwood MC. The stability of diamorphine alone and in combinaison with antiemetics in plastic syringes. Palliative Med 1991 ; 5: 330-333.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.

1970	Revue	Barcia E, Reyes R, Azuara M.L, S?nchez Y, Negro S. Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care. Support Care Cancer 2003 ; 11, 2: 107-113.
1971	Revue	Azuara ML, Sanchez Y, Reyes R, Barcia E. Physical compatibility and in vivo evaluation of drug mixtures forsubcutaneous infusion to cancer patients in palliative care. Support Care Cancer 2001
1974	Revue	Chandler SW, Trissel LA, Weinstein SM Combined administration of opoids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility. J Pain Symptom Manage 1996 ; 12, 3: 168-171.
2024	Revue	Negro S, Martin A, Azuara ML, Sanchez Y, Barcia E. Stability of tramadol and haloperidol for continuous infusion at home. J Pain Symptom Manage 2005 ; 30: 192-199.
2055	Revue	Negro S, Reyes R, Azuara ML, Sanchez Y, Barcia E. Morphine, haloperidol and hyoscine N-butyl bromide combined in sc infusion solutions : compatibility and stability evaluation in terminal oncology patients. Int J Pharm 2006 ; 307: 278-284.
2113	Revue	Jäppinen A, Kokki H, Naaranlahti TJ, Rasi AS. Stability of buprenorphine, haloperidol and glycopyrrolate mixture in a 0.9% sodium chloride solution. Pharm World Sci 1999 ; 21, 6: 272-274.
2125	Revue	Gardiner PR. Compatibility of an injectable oxycodone formulation with typical diluents, syringes, tubings, infusion bags and drugs for potential co-administration. Hospital Pharmacist 2003 ; 10: 354-361.
2166	Revue	Nassr S, Dubuc MC, Lavoie P, Brazier JL. HPLC-DAD methods for studying the stability of solutions containing hydromorphone, ketorolac, haloperidol, midazolam, famotidine, metoclopramide, dimenhydrinate and scopolamine. J Liquid Chrom Rel Technol 2003 ; 26, 17: 2909-2929.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2362	Poster	Trittler R, M?ller S, Esteban M. Morphin-Haloperidol mischungen in PCA Pumpen : Kompatibel? ADKA Congress 2009 2009
2900	Revue	Hines S, Pleasance S. Compatibility of an injectable high strength oxycodone formulation with typical diluents, syringes, tubings,infusion bags and drugs for potential co-administration. EJHP 2009 ; 15, 5: 32-38.
3132	Revue	Negro S, Martin A, Azuara L, Sanchez Y, Barcia E. Compatibility and stability of ternary admixtures of tramadol, haloperidol, and hyoscine. J Palliat Med 2010 ; 13, 3: 273-277.
3134	Revue	Perez Jua En, Maqueda Palau M, Arévalo Rubert Mt, Ribas Nicolau B, Amoros Cerdà SM. Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua. Enferm Intensiva 2010 ; 21: 96-103.
3152	Revue	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3212	Revue	Ribas Nicolau, B.; P?rez Juan, E.; Amor?s Cerd?, S.M.; Ar?valo Rubert, M.J.; Maqueda Palau, M. Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos. Enferm Intensiva 2011 ;22:78-82.

3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3297	Revue	Salmeron-Garcia A, Lopez-Lopez E, Roma E, Cabeza J, Navas N, Capitan-Vallvey L.F. Development of an LC–DAD Method for Analysis of Dexketoprofen, Tramadol, and Haloperidol. Study of the Stability of Mixtures Used for Patient-Controlled Analgesia. Chromatographia 2008 ; 68, 9-10: 767-772.
3332	Laboratoire	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3463	Revue	Eva Perez Juan, Maria Jos? Arévalo Rubert , Silvia Monica Amoros Cerda , Palau M.M, Nicolau B.R. Fármacos en perfusión continua en la unidad de cuidados intensivos: estudio de compatibilidad. Nursing 2011 ; 29 :62-6
3464	Revue	Monica Maqueda-Palau, Eva Pérez-Juan, Maria Josep Arévalo-Rubert, Sylvia Monica Amoros-Cerda, Bàrbara Ribas-Nicolau. Compatibilidad física de la amiodarona en perfusión continua Enferm Clin 2011 21:25-29.
3465	Revue	E. P?rez Juan, M. Maqueda Palau, M. Ar?valo Rubert, B. Ribas Nicolau, S.M. Amor?s Cerd?. Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua. Enferm Intensiva 2010 ;21:96-103.
3466	Revue	B. Ribas Nicolau, E. P?rez Juan, S.M. Amor?s Cerd?, M.J. Ar?valo Rubert, M. Maqueda Palau. Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos Enferm Intensiva 2011 ;22:78-82.
3539	Laboratoire	Bivalirudin (Angiox®) - Summary of Product Characteristics. The Medecines Company 2013
3540	Laboratoire	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3823	Revue	Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l'unité de soins intensifs Pharmactuel 2015 ; 48, 3 : 146-152.
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
4036	Revue	Estan-Cerezo G, Matoses-Chirivella C, Soriano-Iriga L, Murcia-Lopez A.C, Rodrguez-Lucena F.J, Navarro-Ruiz A. Stability and compatibility of ondansetron with haloperidol in parenteral admixtures. EJHP 2017 ;25,4: 200-203.
4082	Revue	Espinosa-Bosch M, Sanchez-Rojas F, Bosche-Ojeda C. Stability of mixtures of ondansetron and haloperidol stored in infusors at different temperatures. EJHP 2018 ; 25, e2
4366	Revue	Estan-Cerezo G, Rodriguez-Lucena F.J, Matoses Chirivella C, Jiminez-Pulido I, Garcia-Monsalve A, Navarro-Ruiz A. Midazolam and haloperidol for palliative sedation: physicochemical stability and compatibility of parenteral admixtures. Braz J Pharm Sci 2019 ;55:e17351
4404	Poster	Müller U, Haller F, Wiedemeier P, Steuer C. Compatibility studies of seven commonly used drugs for parenteral administration in palliative care. JFSPH 2019 2019
4433	Revue	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.

4435	Revue	Hanifah S, Nugroho B.H, Chabib L. Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection. Anaesthesiol Intensive Ther 2020 ; 52, 1: 23-27.
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4650	Laboratoire	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4982	Laboratoire	Diamorphine Hydrochloride 100mg for Injection - Summary of Product Characteristics Updated 06-May-2020. Wockhardt UK Ltd 2020
5073	Laboratoire	Palladone 10 mg/ml solution for injection or infusion - Summary of Product Characteristics Updated 28-Apr-2025. Napp Pharmaceuticals Limited 2025

Dictionnaire

	Neuroleptique		injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Verre
	Glucose 5%		A l'abri de la lumière
	Jour		Stabilité en mélange
	Solvant		Molécule
PVC	Polyvinyl chlorure		Chlorure de sodium 0,9%
?	Non précisée	PP	Polypropylène
POF	Polyolefine		Avec ou sans lumière
EVA	Ethylène vinyl acétate		Seringue polypropylène
	Eau pour préparation injectable		Lumière
	Heure	Ø	Aucun
?	Non précisé		Facteur influençant la stabilité
	Provoque		Dégradation
RL	Ringer lactate	0.45	Chlorure de sodium 0,45%
	Nutrition parentérale (mélange ternaire)	NaH CO3	NaHCO3
	Compatibilités		Précipitation immédiate
	Incompatible		Compatible
15'	Précipitation en 15 minutes		Précipitation en 4 heures
	Incompatibilité non précisée		NaCl 0,9% + bactériosatique
2	Précipitation en 2 heures		Nutrition parentérale (mélange binaire)
	Instabilité de l'émulsion immédiate	1	Précipitation en 1 heure
	Solvant spécifique		Turbidité immédiate
	Voie d'administration		Intramusculaire
	Sous cutanée		Perfusion SC continue
	Bibliographie		Dictionnaire